---
title: "Galapagos NV (GLPG.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/GLPG.US.md"
symbol: "GLPG.US"
name: "Galapagos NV"
industry: "Biotechnology"
datetime: "2026-05-21T20:56:21.361Z"
locales:
  - [en](https://longbridge.com/en/quote/GLPG.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/GLPG.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/GLPG.US.md)
---

# Galapagos NV (GLPG.US)

## Company Overview

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667 that is in phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-21T04:30:18.000Z

**Overall: B (0.30)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 61 / 385 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 292.86% |  |
| Net Profit YoY | 412.73% |  |
| P/B Ratio | 0.00 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 0.00 |  |
| Revenue | 1219200793.54 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 16.26% | A |
| Profit Margin | 46.83% | A |
| Gross Margin | 25.95% | C |
| Revenue YoY | 292.86% | A |
| Net Profit YoY | 412.73% | A |
| Total Assets YoY | 0.00% | D |
| Net Assets YoY | 0.00% | D |
| Cash Flow Margin | -61.70% | E |
| OCF YoY | 292.86% | A |
| Turnover | 0.28 | D |
| Gearing Ratio | 3.53% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Galapagos NV",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "292.86%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "412.73%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "0.00",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "0.00",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "1219200793.54",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "16.26%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "46.83%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "25.95%",
          "rating": "C"
        },
        {
          "name": "Revenue YoY",
          "value": "292.86%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "412.73%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-61.70%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "292.86%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.28",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "3.53%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 5.13 | 12/385 | 5.87 | 5.20 | 5.13 |
| PB | 0.50 | 33/385 | 0.75 | 0.68 | 0.57 |
| PS (TTM) | 1.48 | 38/385 | 7.02 | 6.53 | 1.70 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-07T04:00:00.000Z

Total Analysts: **4**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Hold | 3 | 75% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 27.73 |
| Highest Target | 28.01 |
| Lowest Target | 28.01 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/GLPG.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/GLPG.US/norm.md)
- [Related News](https://longbridge.com/en/quote/GLPG.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/GLPG.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**